Our first proprietary drug candidate platform, SCI-110, combines Dronabinol – the FDA approved synthetic form of THC, with CannAmide™, the Company’s proprietary formulation of palmitoylethanolamide (PEA). Designed to stimulate cannabinoid receptors across the Central Nervous System and inhibit the metabolic degradation of endocannabinoids in order to improve uptake of THC, the expected benefits of SCI-110 are an increase in efficiency of oral administration, and in turn a decrease in dosage requirements, side effects and adverse events. SCI-110 is currently in the clinical trials development stage for the treatment of Tourette Syndrome, Obstructive Sleep Apnea, Alzheimer’s Disease and Agitation.
Our second proprietary drug development platform is SCI-210, which combines cannabidiol (CBD), a non-psychoactive cannabinoid, and CannAmide, the Company’s proprietary PEA formulation. Indications currently being investigated for treatment with SCI-210 include clinical trial for Autism Spectrum Disorder and pre-clinical study for Status Epilepticus – a form of seizures that are severe and sometimes fatal.
SCI-160 is an innovative, proprietary synthetic CB2 receptor agonist created for the treatment of pain and is currently in the pre-clinical stage of our development pipeline. The CB2 receptor agonist used in this formulation – HU-433 – was synthesized by Professor Raphael Mechoulam, Ph.D., Chairman of the SciSparc Scientific Advisory Board and is protected under a patent granted in the U.S. and Europe.